HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.

AbstractBACKGROUND:
We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy.
METHODS:
Using a dose-escalation schedule, CKD-732 doses of 2, 5, or 10 mg/m(2)/d were administered twice weekly for 2 weeks, followed by a 1-week rest. Oxaliplatin (130 mg/m(2)) was administered on day 1, and capecitabine (1,000 mg/m(2) twice a day) was orally administered for 14 days of a 3-week cycle.
RESULTS:
In the group given the 10 mg/m(2)/d dose, two patients experienced dose limiting toxicities (one had grade 3 nausea, insomnia, and fatigue; the other had grade 3 insomnia). The maximum tolerated dose was 10 mg/m(2)/d, and the clinically recommended dose was 5 mg/m(2)/d for CKD-732 in combination with XELOX. Frequently encountered non-hematological grade 3/4 adverse events included insomnia (22.2%), fatigue (11.1%), sensory neuropathy (11.1%), hyperbilirubinemia (11.1%), and dyspnea (11.1%). The area under the concentration-time curve and maximum concentration of CKD-732 increased in a dose-dependent manner. There were no notable effects of CKD-732 on the PK of capecitabine and oxaliplatin-derived platinum.
CONCLUSION:
The Phase II recommended dose of CKD-732 was determined to be 5 mg/m(2)/d, and this dose was safely combined with a conventional dose of capecitabine and oxaliplatin in this patient population. Further studies on the effects of CKD-732 in combination with XELOX and other chemotherapies using a larger study population are warranted.
AuthorsSang Joon Shin, Joong Bae Ahn, Kyung Soo Park, Yoon Jung Lee, Yong Sang Hong, Tae Won Kim, Hye Ryun Kim, Sun Young Rha, Jae Kyung Roh, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung
JournalInvestigational new drugs (Invest New Drugs) Vol. 30 Issue 2 Pg. 672-80 (Apr 2012) ISSN: 1573-0646 [Electronic] United States
PMID21188464 (Publication Type: Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antineoplastic Agents, Phytogenic
  • Cinnamates
  • Cyclohexanes
  • Epoxy Compounds
  • Oxaloacetates
  • Sesquiterpenes
  • Deoxycytidine
  • Capecitabine
  • Irinotecan
  • CKD732
  • Fluorouracil
  • Camptothecin
Topics
  • Adenocarcinoma (blood, drug therapy, mortality, secondary)
  • Adult
  • Aged
  • Angiogenesis Inhibitors (pharmacokinetics)
  • Antineoplastic Agents, Phytogenic (therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Camptothecin (analogs & derivatives, therapeutic use)
  • Capecitabine
  • Cinnamates (pharmacokinetics)
  • Colorectal Neoplasms (blood, drug therapy, mortality, pathology)
  • Cyclohexanes (pharmacokinetics)
  • Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives, blood, pharmacokinetics)
  • Disease Progression
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Epoxy Compounds (pharmacokinetics)
  • Female
  • Fluorouracil (administration & dosage, adverse effects, analogs & derivatives, blood, pharmacokinetics)
  • Humans
  • Irinotecan
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Models, Biological
  • Models, Statistical
  • Oxaloacetates
  • Republic of Korea
  • Sesquiterpenes (pharmacokinetics)
  • Survival Analysis
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: